Aaron W Aday1, Allison B Goldfine2,3, Justin M Gregory4, Joshua A Beckman1. 1. Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 2. Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA. 3. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA. 4. Ian M. Burr Division of Pediatric Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
OBJECTIVE: Insulin resistance is associated with increased lipolysis and elevated concentrations of free fatty acids (FFA), which in turn contribute to impaired vascular function. It was hypothesized that lowering FFA with acipimox, a nicotinic acid derivative that impairs FFA efflux, would improve endothelial function, measured by flow-mediated dilation (FMD), in individuals with metabolic syndrome. METHODS: A total of 18 participants with metabolic syndrome and 17 healthy controls were enrolled and treated with acipimox 250 mg orally every 6 hours or placebo for 7 days in a randomized, double-blind, crossover trial. RESULTS:Acipimox reduced FFA concentrations among individuals with metabolic syndrome to near normal levels (P = 0.01), but there was no change among healthy controls (P = 0.17). Acipimox did not improve endothelial-dependent FMD in either group (metabolic syndrome: P = 0.42; healthy controls: P = 0.16), although endothelial-independent nitroglycerin-mediated dilation among those with metabolic syndrome tended to increase (20.3%, P = 0.06). There were no changes in blood lipids or markers of inflammation following therapy. There was minimal correlation between change in FMD and baseline measures of BMI ( ρ = -0.09) or waist circumference ( ρ = -0.15). CONCLUSIONS: In groups with normal or elevated baseline FFA, short-term reductions do not improve endothelial function assessed by FMD.
RCT Entities:
OBJECTIVE:Insulin resistance is associated with increased lipolysis and elevated concentrations of free fatty acids (FFA), which in turn contribute to impaired vascular function. It was hypothesized that lowering FFA with acipimox, a nicotinic acid derivative that impairs FFA efflux, would improve endothelial function, measured by flow-mediated dilation (FMD), in individuals with metabolic syndrome. METHODS: A total of 18 participants with metabolic syndrome and 17 healthy controls were enrolled and treated with acipimox 250 mg orally every 6 hours or placebo for 7 days in a randomized, double-blind, crossover trial. RESULTS:Acipimox reduced FFA concentrations among individuals with metabolic syndrome to near normal levels (P = 0.01), but there was no change among healthy controls (P = 0.17). Acipimox did not improve endothelial-dependent FMD in either group (metabolic syndrome: P = 0.42; healthy controls: P = 0.16), although endothelial-independent nitroglycerin-mediated dilation among those with metabolic syndrome tended to increase (20.3%, P = 0.06). There were no changes in blood lipids or markers of inflammation following therapy. There was minimal correlation between change in FMD and baseline measures of BMI ( ρ = -0.09) or waist circumference ( ρ = -0.15). CONCLUSIONS: In groups with normal or elevated baseline FFA, short-term reductions do not improve endothelial function assessed by FMD.
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: J T Kuvin; A R Patel; K A Sliney; N G Pandian; W M Rand; J E Udelson; R H Karas Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: A T Santomauro; G Boden; M E Silva; D M Rocha; R F Santos; M J Ursich; P G Strassmann; B L Wajchenberg Journal: Diabetes Date: 1999-09 Impact factor: 9.461
Authors: S V de Kreutzenberg; C Crepaldi; S Marchetto; L Calò; A Tiengo; S Del Prato; A Avogaro Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Friedrich Mittermayer; Georg Schaller; Johannes Pleiner; Katarzyna Krzyzanowska; Stylianos Kapiotis; Michael Roden; Michael Wolzt Journal: J Clin Endocrinol Metab Date: 2007-05-01 Impact factor: 5.958